BioMarin to Present at the Oppenheimer Healthcare Conference
- Press Release
- Source: BioMarin Pharmaceutical Inc.
- On 4:00 pm EDT, Tuesday October 27, 2009
NOVATO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN - News) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Oppenheimer Healthcare Conference in New York City on Tuesday, November 3, 2009 at 1:35 p.m. ET.
Related Quotes
| Symbol | Price | Change |
|---|---|---|
| BMRN | 16.84 | +0.17 |
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.
Contacts:
Investors Media
Eugenia Shen Susan Berg
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 506-6570 (415) 506-6594
Related Headlines
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program - PR Newswire
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme - PR Newswire
- Healthcare Bill Will Be Law By New Year Says Morningstar Strategist - Wall Street Transcript
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food - PR Newswire
- BioMarin to Present at the Credit Suisse Healthcare Conference - PR Newswire
Related Blog Headlines
- BioMarin Purchases Huxley - Zacks.com
- Halftime Report: Trading Market's 5-Day Advance - at CNBC
Sponsored Links
-
Trade Stocks? Try Currency Trading
Trade in a highly trending market 24-hrs a day, 5.5 days a week. GFT. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Super Cheap Car Insurance Quotes
Get Discount Auto Insurance Quotes Online - Rates from $15 / Month.
Tech Ticker Recent Posts
Add Alert Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.